<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Pharmaceutical manufacture for export &#8211; what do you think?</title>
	<atom:link href="http://www.thinkipstrategy.com/ipthinktank/540/pharmaceutical-manufacture-for-export-what-do-you-think/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thinkipstrategy.com/ipthinktank/540/pharmaceutical-manufacture-for-export-what-do-you-think/</link>
	<description>Trusted advisors to the world&#039;s most innovative companies</description>
	<lastBuildDate>Mon, 16 Jan 2012 09:10:00 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
	<item>
		<title>By: Duncan</title>
		<link>http://www.thinkipstrategy.com/ipthinktank/540/pharmaceutical-manufacture-for-export-what-do-you-think/comment-page-1/#comment-1397</link>
		<dc:creator>Duncan</dc:creator>
		<pubDate>Wed, 08 Apr 2009 22:59:09 +0000</pubDate>
		<guid isPermaLink="false">http://localhost:100/thinkipstrategy/?p=540#comment-1397</guid>
		<description>&lt;p&gt;Hey Stan&lt;br /&gt;Thanks for your thoughts.&#160; The limited exception doesn&#039;t and wouldn&#039;t apply to parallel imports which would be an infringement.&#160; So, although it might be more likely in a country, it is still patent infringement, and therefore perhaps not meaningless?&lt;/p&gt;</description>
		<content:encoded><![CDATA[<p>Hey Stan<br />Thanks for your thoughts.&nbsp; The limited exception doesn&#8217;t and wouldn&#8217;t apply to parallel imports which would be an infringement.&nbsp; So, although it might be more likely in a country, it is still patent infringement, and therefore perhaps not meaningless?</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Duncan</title>
		<link>http://www.thinkipstrategy.com/ipthinktank/540/pharmaceutical-manufacture-for-export-what-do-you-think/comment-page-1/#comment-2068</link>
		<dc:creator>Duncan</dc:creator>
		<pubDate>Wed, 08 Apr 2009 22:59:00 +0000</pubDate>
		<guid isPermaLink="false">http://localhost:100/thinkipstrategy/?p=540#comment-2068</guid>
		<description>Hey StanThanks for your thoughts.&#160; The limited exception doesn&#039;t and wouldn&#039;t apply to parallel imports which would be an infringement.&#160; So, although it might be more likely in a country, it is still patent infringement, and therefore perhaps not meaningless?</description>
		<content:encoded><![CDATA[<p>Hey StanThanks for your thoughts.&nbsp; The limited exception doesn&#8217;t and wouldn&#8217;t apply to parallel imports which would be an infringement.&nbsp; So, although it might be more likely in a country, it is still patent infringement, and therefore perhaps not meaningless?</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Stan Abrams</title>
		<link>http://www.thinkipstrategy.com/ipthinktank/540/pharmaceutical-manufacture-for-export-what-do-you-think/comment-page-1/#comment-1396</link>
		<dc:creator>Stan Abrams</dc:creator>
		<pubDate>Wed, 08 Apr 2009 22:56:46 +0000</pubDate>
		<guid isPermaLink="false">http://localhost:100/thinkipstrategy/?p=540#comment-1396</guid>
		<description>&lt;p&gt;

Duncan,&lt;/p&gt;&lt;p&gt;
Interesting issue. Just wondered how parallel imports might fit into the
picture. If you manufacture for export only, one would assume that
re-importation is not possible. For some countries, this is something likely to
happen, though. To the extent that this is likely in a country, this would tend
to make the exportation distinction meaningless.&lt;/p&gt;&lt;p&gt;
--Stan&lt;/p&gt;</description>
		<content:encoded><![CDATA[<p>Duncan,</p>
<p>
Interesting issue. Just wondered how parallel imports might fit into the<br />
picture. If you manufacture for export only, one would assume that<br />
re-importation is not possible. For some countries, this is something likely to<br />
happen, though. To the extent that this is likely in a country, this would tend<br />
to make the exportation distinction meaningless.</p>
<p>
&#8211;Stan</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Stan Abrams</title>
		<link>http://www.thinkipstrategy.com/ipthinktank/540/pharmaceutical-manufacture-for-export-what-do-you-think/comment-page-1/#comment-2067</link>
		<dc:creator>Stan Abrams</dc:creator>
		<pubDate>Wed, 08 Apr 2009 22:56:00 +0000</pubDate>
		<guid isPermaLink="false">http://localhost:100/thinkipstrategy/?p=540#comment-2067</guid>
		<description>

Duncan,
Interesting issue. Just wondered how parallel imports might fit into the
picture. If you manufacture for export only, one would assume that
re-importation is not possible. For some countries, this is something likely to
happen, though. To the extent that this is likely in a country, this would tend
to make the exportation distinction meaningless.
--Stan</description>
		<content:encoded><![CDATA[<p>Duncan,<br />
Interesting issue. Just wondered how parallel imports might fit into the<br />
picture. If you manufacture for export only, one would assume that<br />
re-importation is not possible. For some countries, this is something likely to<br />
happen, though. To the extent that this is likely in a country, this would tend<br />
to make the exportation distinction meaningless.<br />
&#8211;Stan</p>
]]></content:encoded>
	</item>
</channel>
</rss>

